Q3 EPS Estimates for Oncobiologics Increased by Analyst

Oncobiologics, Inc. (NASDAQ:OTLK) – Equities research analysts at Brookline Capital Markets raised their Q3 2026 earnings per share (EPS) estimates for Oncobiologics in a research note issued to investors on Monday, March 30th. Brookline Capital Markets analyst K. Dolliver now anticipates that the company will post earnings of ($0.13) per share for the quarter, up from their prior forecast of ($0.17). The consensus estimate for Oncobiologics’ current full-year earnings is ($2.27) per share. Brookline Capital Markets also issued estimates for Oncobiologics’ Q4 2026 earnings at ($0.11) EPS, FY2026 earnings at ($0.55) EPS and FY2027 earnings at ($0.14) EPS.

Oncobiologics (NASDAQ:OTLK) last released its earnings results on Tuesday, February 17th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). The company had revenue of ($1.21) million during the quarter, compared to analysts’ expectations of $3.14 million.

A number of other research firms have also issued reports on OTLK. Ascendiant Capital Markets lowered their target price on Oncobiologics from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, March 11th. Chardan Capital reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. HC Wainwright reaffirmed a “neutral” rating on shares of Oncobiologics in a report on Wednesday, February 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncobiologics in a report on Friday, March 27th. Finally, Wall Street Zen lowered Oncobiologics from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.50.

Oncobiologics Stock Up 6.2%

NASDAQ:OTLK opened at $0.21 on Tuesday. The business’s 50-day moving average price is $0.37 and its 200 day moving average price is $1.01. The firm has a market cap of $18.02 million, a P/E ratio of -0.08 and a beta of 0.18. Oncobiologics has a 52-week low of $0.16 and a 52-week high of $3.39.

Hedge Funds Weigh In On Oncobiologics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its position in shares of Oncobiologics by 865.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,477 shares of the company’s stock valued at $39,000 after purchasing an additional 21,941 shares during the period. AQR Capital Management LLC boosted its position in shares of Oncobiologics by 42.7% in the 1st quarter. AQR Capital Management LLC now owns 84,671 shares of the company’s stock valued at $103,000 after purchasing an additional 25,351 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in shares of Oncobiologics by 74.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 103,524 shares of the company’s stock valued at $126,000 after purchasing an additional 44,063 shares during the period. Institutional investors and hedge funds own 11.20% of the company’s stock.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company specializing in the development of biosimilar therapeutics for cancer and autoimmune diseases. Leveraging recombinant DNA technology and advanced formulation platforms, the company aims to create high-quality, cost-effective alternatives to originator biologic drugs. Oncobiologics’ research focus includes monoclonal antibodies and growth factors that support oncology treatment and immunomodulation.

Founded in 2005 and headquartered in Marlborough, Massachusetts, Oncobiologics maintains research facilities in the Greater Boston area and an integrated manufacturing site in Hyderabad, India, through its wholly owned subsidiary.